Mandate

Vinge has advised Hansa Biopharma in connection with a directed share issue of SEK 415.9 million

Vinge has advised Hansa Biopharma in connection with a directed share issue through which the company raises proceeds of SEK 415.9 million before transaction costs.

Hansa Biopharma is a commercial-stage biopharmaceutical company on a mission to develop and commercialize innovative, lifesaving and life-altering treatments for patients with rare immunological conditions. Hansa Biopharma’s ordinary share is listed on Nasdaq Stockholm.

Vinge’s team consisted of Dain Hård Nevonen, Amanda Knutsson, Anders Sundin Lundberg and Petter Hellgren.

Related

Vinge advises Calliditas Therapeutics in connection with Asahi Kasei Corporation’s public takeover offer

On 28 May 2024, Asahi Kasei Corporation announced a public takeover offer to the shareholders and holders of American Depositary Shares in Calliditas Therapeutics AB (publ) (”Calliditas Therapeutics”) to acquire all shares and American Depositary Shares (each representing two shares) in Calliditas Therapeutics.
May 28, 2024

Vinge has advised Alder on the establishment of Alder III

Vinge has advised Alder on the establishment of Alder's third and largest fund to date, Alder III.
May 27, 2024